Year in Review: Hematologic Malignancies

(MedPage Today) -- The year in hematologic malignancy management was punctuated by the deadly COVID-19 pandemic, a flurry of FDA approvals ushering in new therapies, and continued steady advances in cellular products and other treatments for leukemia...